{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:07:36Z","timestamp":1778220456815,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40262-023-01241-7","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T11:01:33Z","timestamp":1683370893000},"page":"891-904","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug\u2013Drug Interactions in Children"],"prefix":"10.1007","volume":"62","clinical-trial-number":[{"clinical-trial-number":"nct02633709","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03032172","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02908685","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02913482","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03988907","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9703-7269","authenticated-orcid":false,"given":"Yumi","family":"Cleary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidemarie","family":"Kletzl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Grimsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Heinig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2446-6895","authenticated-orcid":false,"given":"Kayode","family":"Ogungbenro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna Elisabeth","family":"Silber Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-6570","authenticated-orcid":false,"given":"Leon","family":"Aarons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Galetin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,6]]},"reference":[{"issue":"1","key":"1241_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365.","journal-title":"Cell"},{"key":"1241_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D'Amico","year":"2011","unstructured":"D\u2019Amico A, et al. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71.","journal-title":"Orphanet J Rare Dis"},{"issue":"15","key":"1241_CR3","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni H, et al. Discovery of risdiplam, a selective survival of motor neuron-2 ( SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem. 2018;61(15):6501\u201317.","journal-title":"J Med Chem"},{"key":"1241_CR4","unstructured":"European Medicines Agency. Evrysdi (risdiplam). 2021. https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-evrysdi_en.pdf. Accessed Feb 2022."},{"key":"1241_CR5","unstructured":"US FDA. FDA Approves Oral Treatment for Spinal Muscular Atrophy. 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-oral-treatment-spinal-muscular-atrophy. Accessed Nov 2022."},{"key":"1241_CR6","unstructured":"US FDA. EVRYSDI\u2122 (risdiplam) for oral solution. Highlights of Prescribing Information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213535Orig1s000lbl.pdf. Accessed Nov 2022."},{"key":"1241_CR7","unstructured":"US FDA. Highlights of prescribing information. EVRYSDI (risdiplam) for oral solution. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213535s003s005lbl.pdf. Accessed Nov 2022."},{"issue":"1","key":"1241_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1124\/dmd.121.000563","volume":"50","author":"S Fowler","year":"2022","unstructured":"Fowler S, et al. Addressing today\u2019s absorption, distribution, metabolism, and excretion (ADME) challenges in the translation of in vitro ADME characteristics to humans: a case study of the SMN2 mRNA splicing modifier risdiplam. Drug Metab Dispos. 2022;50(1):65\u201375.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1241_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bcp.13786","volume":"85","author":"S Sturm","year":"2019","unstructured":"Sturm S, et al. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. Br J Clin Pharmacol. 2019;85(1):181\u201393.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1241_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.447","volume":"6","author":"A Poirier","year":"2018","unstructured":"Poirier A, et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect. 2018;6(6): e00447.","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"1241_CR11","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1203\/00006450-200202000-00018","volume":"51","author":"SB Koukouritaki","year":"2002","unstructured":"Koukouritaki SB, et al. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res. 2002;51(2):236\u201343.","journal-title":"Pediatr Res"},{"issue":"4","key":"1241_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2125.2010.03876.x","volume":"71","author":"M Shimizu","year":"2011","unstructured":"Shimizu M, et al. Developmental variations in metabolic capacity of flavin-containing mono-oxygenase 3 in childhood. Br J Clin Pharmacol. 2011;71(4):585\u201391.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1241_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1124\/jpet.117.243113","volume":"363","author":"M Xu","year":"2017","unstructured":"Xu M, et al. Genetic and nongenetic factors associated with protein abundance of flavin-containing monooxygenase 3 in human liver. J Pharmacol Exp Ther. 2017;363(2):265\u201374.","journal-title":"J Pharmacol Exp Ther"},{"key":"1241_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev.pharmtox.46.120604.141043","volume":"46","author":"JR Cashman","year":"2006","unstructured":"Cashman JR, Zhang J. Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol. 2006;46:65\u2013100.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"1241_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/FPC.0b013e32835c3b48","volume":"23","author":"AJ Bloom","year":"2013","unstructured":"Bloom AJ, et al. Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption. Pharmacogenet Genom. 2013;23(2):62\u20138.","journal-title":"Pharmacogenet Genom"},{"issue":"1","key":"1241_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0009-2797(97)00055-0","volume":"106","author":"LH Overby","year":"1997","unstructured":"Overby LH, Carver GC, Philpot RM. Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact. 1997;106(1):29\u201345.","journal-title":"Chem Biol Interact"},{"issue":"10","key":"1241_CR17","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1124\/dmd.104.000802","volume":"33","author":"P Parte","year":"2005","unstructured":"Parte P, Kupfer D. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin. Drug Metab Dispos. 2005;33(10):1446\u201352.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1241_CR18","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/cpt.2384","volume":"110","author":"Y Cleary","year":"2021","unstructured":"Cleary Y, et al. Model-based drug\u2013drug interaction extrapolation strategy from adults to children: risdiplam in pediatric patients with spinal muscular atrophy. Clin Pharmacol Ther. 2021;110(6):1547\u201357.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1241_CR19","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/jcph.585","volume":"56","author":"VV Upreti","year":"2016","unstructured":"Upreti VV, Wahlstrom JL. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2016;56(3):266\u201383.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"1241_CR20","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1517\/17425250802522188","volume":"4","author":"JR Cashman","year":"2008","unstructured":"Cashman JR. Role of flavin-containing monooxygenase in drug development. Expert Opin Drug Metab Toxicol. 2008;4(12):1507\u201321.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1241_CR21","unstructured":"US FDA. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed Nov 2022."},{"issue":"5","key":"1241_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/jcph.13","volume":"53","author":"F Salem","year":"2013","unstructured":"Salem F, Rostami-Hodjegan A, Johnson TN. Do children have the same vulnerability to metabolic drug-drug interactions as adults? A critical analysis of the literature. J Clin Pharmacol. 2013;53(5):559\u201366.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"1241_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2165\/00003088-200645070-00004","volume":"45","author":"AN Edginton","year":"2006","unstructured":"Edginton AN, et al. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet. 2006;45(7):683\u2013704.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1241_CR24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","volume":"45","author":"TN Johnson","year":"2006","unstructured":"Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45(9):931\u201356.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1241_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40262-014-0140-7","volume":"53","author":"F Salem","year":"2014","unstructured":"Salem F, et al. A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. Clin Pharmacokinet. 2014;53(7):625\u201336.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1241_CR26","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1002\/cpt.2134","volume":"109","author":"J Lang","year":"2021","unstructured":"Lang J, et al. Impact of hepatic CYP3A4 ontogeny functions on drug\u2013drug interaction risk in pediatric physiologically-based pharmacokinetic\/pharmacodynamic modeling: critical literature review and ivabradine case study. Clin Pharmacol Ther. 2021;109(6):1618\u201330.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1241_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1046\/j.1365-2125.2001.01370.x","volume":"51","author":"TN Johnson","year":"2001","unstructured":"Johnson TN, et al. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol. 2001;51(5):451\u201360.","journal-title":"Br J Clin Pharmacol"},{"key":"1241_CR28","unstructured":"Gabrielsson J, Weiner D. Pharmacokinetic\u2013pharmacodynamic data analysis: concepts and applications. 1997."},{"issue":"29","key":"1241_CR29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jxb\/10.2.290","volume":"10","author":"FJ Richards","year":"1959","unstructured":"Richards FJ. A flexible growth function for empirical use. J Exp Bot. 1959;10(29):290\u2013300.","journal-title":"J Exp Bot"},{"issue":"1","key":"1241_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/138920007779315053","volume":"8","author":"ZE Barter","year":"2007","unstructured":"Barter ZE, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab. 2007;8(1):33\u201345.","journal-title":"Curr Drug Metab"},{"issue":"1","key":"1241_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1124\/dmd.121.000623","volume":"50","author":"JS Leeder","year":"2022","unstructured":"Leeder JS, et al. Ontogeny of scaling factors for pediatric physiology-based pharmacokinetic modeling and simulation: microsomal protein per gram of liver. Drug Metab Dispos. 2022;50(1):24\u201332.","journal-title":"Drug Metab Dispos"},{"key":"1241_CR32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"1241_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s11095-018-2458-6","volume":"35","author":"JM Brussee","year":"2018","unstructured":"Brussee JM, et al. Characterization of intestinal and hepatic CYP3A-mediated metabolism of midazolam in children using a physiological population pharmacokinetic modelling approach. Pharm Res. 2018;35(9):182.","journal-title":"Pharm Res"},{"key":"1241_CR34","doi-asserted-by":"crossref","unstructured":"Nagar S et al. Enzyme kinetics in drug metabolism: fundamentals and applications. Methods Mol Biol. 2021;2342:551\u201393.","DOI":"10.1007\/978-1-0716-1554-6"},{"issue":"1","key":"1241_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2133\/dmpk.23.54","volume":"23","author":"M Shimizu","year":"2008","unstructured":"Shimizu M, et al. Complex mechanism underlying transcriptional control of the haplotyped flavin-containing monooxygenase 3 (FMO3) gene in Japanese: different regulation between mutations in 5\u2032-upstream distal region and common element in proximal region. Drug Metab Pharmacokinet. 2008;23(1):54\u20138.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"10","key":"1241_CR36","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2165\/00003088-200645100-00005","volume":"45","author":"AN Edginton","year":"2006","unstructured":"Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006;45(10):1013\u201334.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1241_CR37","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1124\/dmd.115.068643","volume":"44","author":"TN Johnson","year":"2016","unstructured":"Johnson TN, Jamei M, Rowland-Yeo K. How does in vivo biliary elimination of drugs change with age? Evidence from in vitro and clinical data using a systems pharmacology approach. Drug Metab Dispos. 2016;44(7):1090\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1241_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.abb.2007.04.014","volume":"464","author":"CK Yeung","year":"2007","unstructured":"Yeung CK, Adman ET, Rettie AE. Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria. Arch Biochem Biophys. 2007;464(2):251\u20139.","journal-title":"Arch Biochem Biophys"},{"key":"1241_CR39","unstructured":"US FDA. Center for Drug Evaluation and Research. Application Number: 213535Orig1s000 Clinical Pharmacology Review(s). 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213535Orig1s000ClinPharmR.pdf. Accessed May 2022."},{"issue":"1","key":"1241_CR40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1124\/dmd.105.006874","volume":"34","author":"A Galetin","year":"2006","unstructured":"Galetin A, et al. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos. 2006;34(1):166\u201375.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1241_CR41","first-page":"81","volume":"12","author":"RS Obach","year":"2009","unstructured":"Obach RS. Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Curr Opin Drug Discov Devel. 2009;12(1):81\u20139.","journal-title":"Curr Opin Drug Discov Devel"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01241-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01241-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T15:13:33Z","timestamp":1686323613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01241-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1241"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01241-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,6]]},"assertion":[{"value":"19 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yumi Cleary, Heidemarie Kletzl, Paul Grimsey, Katja Heinig, Hanna E. Silber Baumann, Nicolas Frey and Michael Gertz are employees of F. Hofmann-La Roche, Ltd, and hold stocks\/stock options with F. Hoffmann-La Roche, Ltd. Kayode Ogungbenro, Leon Aarons and Aleksandra Galetin declared no competing interests for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All relevant study documents were approved by the Institutional Review Board and all subjects or their guardians signed the informed consent prior to enrolment. The studies were conducted in full conformance with the principles of the Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the studies discussed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study was funded by F. Hoffmann-La Roche Ltd. Open access publication of this manuscript was sponsored by F. Hoffmann-La Roche, Ltd.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Qualified researchers may request access to individual patient-level data through the clinical study data request platform (). Further details on Roche\u2019s criteria for eligible studies are available at . For further details on Roche\u2019s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}